Drug Trial Radar · NCT00986154
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Last checked: Nov 20, 2026Latest source record: Mar 5, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8,292
Actual
Start
Oct 2009
Primary completion
Apr 2013
Study completion Apr 2013
Sponsor
- Lead sponsor
- Daiichi SankyoDaiichi Sankyo (DSNKY)
- Sponsor type
- Industry
- First posted
- Sep 29, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
Conditions
- Venous Thromboembolism
- Deep Vein Thrombosis (DVT)
- Pulmonary Embolism (PE)
- Thromboembolism
- Venous Thrombosis
Interventions
edoxaban tosylate(DU-176b)Drug
edoxaban tosylate(DU-176b), film-coated tablet for oral use, 30 mg, two tablets (60 mg) once daily, maximum of 12 months treatment
low molecular weight heparin/unfractionated heparinDrug
LMW heparin - subcutaneous injection, 1 mg/Kg twice daily or 1.5 mg/Kg once daily. Unfractionated heparin - 5,000 IU bolus intravenous administration, 1,300 IU/hour continuous infusion, minimum of 5 days and maximum of about 12 days treatment
warfarinDrug
tablet for oral use; 0.5 mg, 1 mg, 2.5 mg, 5 mg; daily dosage, adjusted to maintain international normalized ratio (INR) between 2.0 and 3.0; maximum of 12 months treatment
Primary outcomes
What the sponsor says the trial is designed to measure.
- Symptomatic Recurrent VTE, i.e., the Composite of DVT, Non-fatal PE, and Fatal PETime frame: 12 months from time of randomization
Locations
454 sites in 38 countries. Site status is shown where the registry gives one.
Investigational Site 7103
Mobile, Alabama
Investigational Site 7132
Montgomery, Alabama
Investigational Site 7126
Phoenix, Arizona
Investigational Site 7139
Little Rock, Arkansas
Investigational Site 1070
Anaheim, California
Investigational Site 7125
Los Alamitos, California
Investigational Site 1093
Monterey, California
Investigational Site 1069
Palm Springs, California
Investigational Site 7150
San Diego, California
Investigational Site 1089
Vista, California
Investigational Site 1012
Aurora, Colorado
Investigational Site 1013
Boulder, Colorado
Investigational Site 1017
Denver, Colorado
Investigational Site 1018
Lakewood, Colorado
Investigational Site 1019
Littleton, Colorado
Investigational Site 1022
Thornton, Colorado
Investigational Site 1023
Thornton, Colorado
Site not named
Brandon, Florida
Investigational Site 1071
Clearwater, Florida
Investigational Site 7117
Fort Myers, Florida
Investigational Site 7106
Gainesville, Florida
Investigational Site 1005
Ocoee, Florida
Investigational Site 1006
Orlando, Florida
Investigational Site 7144
Sarasota, Florida
Investigational Site 7127
St. Petersburg, Florida
Investigational Site 1007
Winter Park, Florida
Investigational Site 7104
Albany, Georgia
Investigational Site 1095
Columbus, Georgia
Investigational Site 1080
Jonesboro, Georgia
Investigational Site 7146
Savannah, Georgia
Investigational Site 1098
Park Ridge, Illinois
Site not named
Carmel, Indiana
Investigational Site 7115
Paducah, Kentucky
Investigational Site 1065
Covington, Louisiana
Investigational Site 1068
Baltimore, Maryland
Investigational Site 1037
Westminster, Maryland
Investigational Site 1038
Westminster, Maryland
Investigational Site 7133
Kansas City, Missouri
Investigational Site 7147
Butte, Montana
Investigational Site 1039
Las Vegas, Nevada
Showing 40 of 454 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.